Background: Globally, hepatocellular carcinoma (HCC) is the sixth most frequent malignancy with a high incidence and a poor prognosis. Immune cell infiltration (ICI) underlies both the carcinogenesis and immunogenicity of tumors. However, a comprehensive classification system based on the immune features for HCC remains unknown.Methods: The HCC dataset from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) cohorts was used in this study. The ICI patterns of 571 patients were characterized using two algorithms: the patterns were determined based on the ICI using the ConsensusClusterPlus package, and principal component analysis (PCA) established the ICI scores. Differences in the immune landscape, biological function, and somatic mutations across ICI scores were evaluated and compared, followed by a predictive efficacy evaluation of ICI scores for immunotherapy by the two algorithms and validation using an external immunotherapy cohort.Results: Based on the ICI profile of the HCC patients, three ICI patterns were identified, including three subtypes having different immunological features. Individual ICI scores were determined; the high ICI score subtype was characterized by enhanced activation of immune-related signaling pathways and a significantly high tumor mutation burden (TMB); concomitantly, diminished immunocompetence and enrichment of pathways associated with cell cycle and RNA degradation were found in the low ICI score subtype. Taken together, our results contribute to a better understanding of an active tumor and plausible reasons for its poor prognosis.Conclusion: The present study reveals that ICI scores may serve as valid prognostic biomarkers for immunotherapy in HCC.
Recognition of excessive activation of hepatic stellate cells (HSCs) in liver fibrosis prompted us to investigate the regulatory mechanisms of HSCs. We aimed to examine the role of O-GlcNAcylation modification of alanine, serine, cysteine transporter 2 (ASCT2) in HSCs and liver fibrosis.
1 January 2025 in International Journal of Genomics
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer mortality, with limited treatment options due to its high heterogeneity. SPP1 + tumor‐associated macrophages are emerging as key regulators of the tumor immune microenvironment and disease progression. Methods: We integrated scRNA‐seq data from the GEO database with bulk transcriptomic data from TCGA and ICGC. Immune cell subsets were identified through clustering and ligand–receptor interaction analyses. Prognostic genes associated with SPP1 + macrophages were screened using univariate Cox and Lasso regression. A risk model was built and validated using survival analysis and ROC curves. A multialgorithm AI framework was applied to enhance model performance. Results: Twelve immune cell types were identified, with SPP1 + macrophages showing strong interactions with tumor and immune cells. A seven‐gene signature (SNX5, YBX1, GNPD1, RAB32, TPM3, ATP6V0B, and RAB7A) was constructed, effectively stratifying patients by survival risk in both TCGA and ICGC cohorts. The model showed strong predictive power with high AUC values and a significant correlation between gene expression and risk scores. Conclusion: SPP1 + macrophages play a crucial role in HCC immune modulation and progression. The gene signature developed provides a reliable tool for prognosis and may inform personalized treatment. This SPP1 + macro‐associated signature offers a novel and robust biomarker for prognosis and may guide precision immunotherapy strategies in HCC.
14 June 2025 in International Journal of Biological Macromolecules
Activated hepatic stellate cells (HSCs) are central to hepatic fibrosis pathogenesis, driving excessive extracellular matrix deposition and pathological angiogenesis. Despite their therapeutic potential, conventional antifibrotic agents face challenges in selectively targeting HSCs, limiting efficacy and increasing off-target toxicity. Here, we address this limitation by leveraging the overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) on activated HSCs to develop pPB/AST NLCs, a nanostructured lipid carriers (NLCs) system conjugated with the PDGFR-β-targeting pPB peptide for delivery of astragaloside IV (AST). Cellular uptake studies in TGF-β1-activated HSCs revealed a significant increase for pPB peptide-mediated NLCs compared to non-targeted NLCs, with co-localization analysis confirming PDGFR-β-dependent internalization. In vivo imaging further confirmed selective hepatic accumulation and prolonged retention of pPB peptide-mediated NLCs, without cytotoxicity or systemic toxicity. pPB/AST NLCs enabled selective accumulation in fibrotic livers, achieving superior efficacy in mitigating hepatic fibrosis by attenuating collagen deposition, reducing liver-to-body weight ratios, and suppressing hepatocellular injury biomarkers through PDGFR-β-targeted engagement on activated HSCs. Histopathological improvements included diminished fibrotic progression, collagen accumulation, and inflammatory cell infiltration, accompanied by significant reductions in pro-fibrotic markers and pro-inflammatory cytokines. Quantitative decreases in hepatic hydroxyproline and α-SMA levels corroborated attenuated injury, while suppression of pathological angiogenesis highlighted additional therapeutic benefits.